SUVN-911 is primarily explored for its potential therapeutic applications in the treatment of neurological and psychiatric disorders. It acts as a selective antagonist for the 5-HT6 receptor, which is implicated in cognitive processes and mood regulation. Research indicates its potential use in addressing conditions such as Alzheimer’s disease, where it may help improve memory and cognitive function by modulating serotonin signaling in the brain. Additionally, it is being investigated for its efficacy in managing symptoms of depression and anxiety, offering a novel approach to treatment by targeting specific serotonin receptors. Preclinical studies suggest that SUVN-911 could also play a role in reducing neuroinflammation and promoting neuroprotection, making it a promising candidate for further development in neurodegenerative and mental health therapies.